FL-KNOWBE4
KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, today released its new 2024 Phishing by Industry Benchmarking Report to measure an organization’s Phish-prone™ Percentage (PPP), which indicates how many of their employees are likely to fall for phishing or social engineering scams.
This year’s report shows that according to baseline testing conducted across all industries, without security awareness training, 34.3% of employees are likely to click on malicious links or comply with fraudulent requests. This is an increase of over one percent in comparison to the 2023 report and highlights the importance of building a strong security culture within organizations to mitigate the human risk that exists when safeguarding against cyber threats.
KnowBe4 analyzed over 54 million simulated phishing tests across more than 11.9 million users from 55,675 organizations in 19 different industries. The resulting baseline PPP measures the percentage of employees in organizations that had not conducted any KnowBe4 security training, who clicked a simulated phishing email link or opened an infected attachment during testing.
The report highlights a key fact: when simulated phishing security testing is integrated with security awareness training, it works. Organizations that commit to regular security awareness training and testing after the initial baseline test saw an average PPP drop to just 18.9% within 90 days. After 12 months of continuous training and testing, the PPP plummeted even further to 4.6%. These results show that to transform cybersecurity culture, existing habits first need to be broken to make way for more secure ones. As employees start to embrace new behaviors, they become habits, over time evolving into standard practices that shape organizational culture and, in turn, creating a workforce that instinctively makes security a priority in their day-to-day work.
Industries particularly vulnerable to cyber threats, scoring the highest PPP, and in dire need of security awareness training are also discussed in the report. The healthcare and pharmaceutical industry remains in the high-risk category with the highest PPP across small- and large-sized organizations scoring 34.7% and 51.4%, respectively. Across medium-sized organizations, the hospitality industry took top billing for the second time in three years with a score of 39.7%.
This report reinforces the crucial role the human element plays in cybersecurity. Although technology is important for preventing and recovering from cyberattacks, human error is still a big contributing factor to data breaches. In fact, according to Verizon's 2024 Data Breach Investigations report, 68% of data breaches were due to accidental actions, the use of stolen credentials, social engineering and malicious privilege misuse. Even though this is an improvement from last year’s 74%, organizations must continue to focus on strengthening the human firewall to safeguard against cyber threats.
An emerging threat vector highlighted in this year’s report is the rapid adoption of AI in certain industries which presents additional risks if not implemented with strong cybersecurity measures.
"The data does not lie; regular and focused security training reshapes how employees interact with potential threats. Our goals are to educate and change behaviors, for employees to instinctively put security first," says Stu Sjouwerman, CEO of KnowBe4. "Furthermore, we are seeing more sophisticated cyber threats emerge because of AI and the need for training is imperative.”
This year’s report also examines international phishing benchmarks from North America, South America, Europe, United Kingdom & Ireland, Africa, Asia, Australia and New Zealand.
To download a copy of the 2024 KnowBe4 Phishing by Industry Benchmarking Report, click here.
About KnowBe4
KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, is used by more than 65,000 organizations around the globe. Founded by IT and data security specialist Stu Sjouwerman, KnowBe4 helps organizations address the human element of security by raising awareness about ransomware, CEO fraud and other social engineering tactics through a new-school approach to awareness training on security. The late Kevin Mitnick, who was an internationally recognized cybersecurity specialist and KnowBe4’s Chief Hacking Officer, helped design the KnowBe4 training based on his well-documented social engineering tactics. Organizations rely on KnowBe4 to mobilize their end users as their last line of defense and trust the KnowBe4 platform to strengthen their security culture and reduce human risk.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604089157/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press release
Ad hoc announcement pursuant to Art. 53 LR Approximately 7% of people in the United States (U.S.) have atopic dermatitis – a common, chronic, and flaring inflammatory skin disease, characterized by persistent itch and recurrent skin lesions1-4 While currently available treatments may improve some signs and symptoms of the disease, many patients do not respond optimally to approved therapies and do not experience itch relief and clear skin to the same degree2,5-7 Nemluvio® (nemolizumab) is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and epidermal dysregulation in atopic dermatitis2,9-11 This approval follows Nemluvio’s recent approval for the treatment of adults with prurigo nodularis from the U.S. Food and Drug Administration earlier in August 202412 Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug
Andersen Global forstærker sin dækning af Asien-Stillehavsregionen med ejendomsrådgivere i Australien13.12.2024 19:39:00 CET | Pressemeddelelse
Andersen Global styrker sin platform i Asien og Stillehavsregionen gennem en samarbejdsaftale med Charter Keck Cramer, der er et af Australiens førende, uafhængige ejendomsrådgivningsfirmaer. Det, der i 1970 begyndte som en lille virksomhed, Charter Keck Cramer, har siden udviklet sig til et tværfagligt firma med mere end 170 eksperter, der er fordelt på fem kontorer i Australien og Singapore. Firmaet tilbyder et omfattende udvalg af ejendomsrelaterede ydelser, herunder værdiansættelser inden for bolig- og erhvervsejendomme, ejendoms- og udviklingsrådgivning, ejendomsdata og analyser samt strategisk planlægning og byøkonomi samt kvantitetsopmåling. Charter Keck Cramer betjener en mangfoldig australsk og international kundebase, herunder offentlige og private virksomheder, ejere og udviklere, større banker og finansielle institutioner, institutionelle ejere og truster, statslige organer og familiekontorer. "Vores vækst over de seneste 54 år er drevet af vores uafhængige, skræddersyede t
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press release
Businesses Must Employ a Multi-Layered Approach to Fight GenAI Fraud Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unli
Capcom Announces Onimusha Way of the Sword, Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom